The BODE Index is a multidimensional prognostic tool used to assess the severity and predict the risk of mortality in patients with Chronic Obstructive Pulmonary Disease (COPD). Unlike measures that rely on a single parameter (like FEV1 alone), the BODE index integrates four distinct components to provide a more comprehensive view of the systemic impact of the disease. The acronym BODE stands for its components: (1)Body-Mass Index (BMI), where points are awarded for low BMI (≤ 21 kg/m²), reflecting the negative impact of cachexia; (2) AirflowObstruction, measured by the post-bronchodilator FEV1 (Forced Expiratory Volume in 1 second), with points increasing as FEV1 decreases; (3)Dyspnea (shortness of breath), assessed using a standardized scale, typically the modified Medical Research Council (mMRC) dyspnea scale, where more points are given for greater perceived breathlessness; and (4)Exercise Capacity, measured by the distance walked in the 6-minute walk test (6MWT), with points increasing as the distance walked decreases. Each component is scored on a point scale (e.g., 0-3 for FEV1, 0-1 for BMI, 0-3 for mMRC, 0-3 for 6MWT), and the points are summed to yield a total score, typically ranging from 0 to 10. A higher total BODE score correlates with increased severity and a higher risk of mortality. This score helps stratify patients (e.g., low, intermediate, high risk) and guides therapeutic management and discussions about prognosis.